Covidien

Integra LifeSciences Holdings Corporation is to acquire Covidien’s Confluent Surgical product lines, including surgical sealants, adhesion barrier, and, most significantly, … continue reading “Integra Seals Duraseal™ Deal”

Covidien has released positive final results from its DURABILITY II study and promising preliminary data from its DEFINITIVE AR Peripheral Artery Disease (PAD) trial involving some of its technologies. The results are sure to fuel its ongoing push into the peripheral vascular therapy area.

Biomedical technology company SetPoint Medical,developing neuromodulation therapies for inflammatory diseases, has secured $27 million in financing from its current investors along with new investors who’s names you might recognise.

Covidien has completed the separation of its Pharmaceuticals business, which is now held by Mallinckrodt plc, a new independent company. Mallinckrodt will begin “regular way” trading on the New York Stock Exchange today under the symbol “MNK.”

Covidien has announced that the final results of the PUFs (Pipeline for Uncoilable or Failed Aneurysms) clinical study of its … continue reading “Pivotal Study Results For Covidien’s Pipeline™ Embolization Device”

Masimo, the inventor of measure-through motion and low perfusion pulse oximetry today renewed its $1,000,000 guarantee that Masimo SET® Pulse Oximetry and rainbow® Pulse CO-Oximetry™ will outperform all Nellcor™ pulse oximeters, including the three that Covidien recently announced have received FDA 510(k) clearance with motion claims.

Covidien’s Nellcor™ pulse oximetry systems have received U.S. FDA 510(k) clearance for so-called “motion” claims. This makes Covidien the first company to receive FDA clearance for a motion-tolerant bedside pulse oximeter portfolio.

The FDA has issued a warning to healthcare professionals that stolen Covidien stapler reloads may be in circulation. The reloads are labelled sterile, but were stolen from the company prior to sterilisation taking place.

Covidien and Mallinckrodt will go their separate ways shortly as the division sees itself turning into a publicly traded specialty pharma business. Strong pharma sales presage the event (as do declining sales in its imaging products).

Covidien has voluntarily recalled certain Power Pac batteries for its Newport™ HT70 and HT70 Plus ventilators following customers reporting units alarming and switching to internal backup battery sooner than expected while the ventilator is being operated on Power Pac battery.

One of those promotional hook-ups that makes perfect sense sees Covidien agree to start distributing Vida Diagnostic’s interventional pulmonology diagnostic and planning software alongside its own i-Logic advanced bronchoscopy system.

Covidien has won a patent infringement suit against Ethicon Endo-Surgery, Inc., a Johnson & Johnson company, relating to Ethicon’s Harmonic® line of ultrasonic surgical products.

Covidien has completed patient enrollment in its iliac stent clinical study series. The series is composed of two prospective, multinational, multicenter studies – VISIBILITY Iliac and DURABILITY Iliac.

Interventional Neurology’s on-off relationship with mechanical thrombectomy might be back on with this solid looking data from Covidien’s STAR study into the safety and efficacy of the Solitaire FR device in AIS patients.

Covidien has gained CE Mark approval for its EverFlex™ Self-expanding Peripheral Stent with Entrust™ Delivery System which it says is designed to allow physicians to consistently place stents in the desired location with accuracy and ease.

Covidien has announced the commercial launch of the OneShot™ Renal Denervation System, an over the wire balloon-based irrigated catheter technology for the treatment of high blood pressure or hypertension.